Publications by authors named "A Bicker"
Background: Breast cancer is the most common type of cancer worldwide. Cyclin-dependent kinase inhibition is one of the backbones of metastatic breast cancer therapy. However, there are a significant number of therapy failures.
View Article and Find Full Text PDFEvaluation of the safety of inpatient empagliflozin in a real-world setting.
Proc (Bayl Univ Med Cent)
August 2023
Background: Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor recommended by the American Diabetes Association for outpatient use. Support for its inpatient role is not well established due to possible safety concerns.
Methods: This was a retrospective study at an academic medical center between January 1, 2021, and December 31, 2021, evaluating the safety and efficacy of empagliflozin compared to other oral antihyperglycemic agents.
Myoglobin (MB) is expressed in different cancer types and may act as a tumor suppressor in breast cancer. The mechanisms by which basal MB expression level impacts murine mammary tumorigenesis are unclear. We investigated how MB expression in breast cancer influences proliferation, metastasis, tumor hypoxia, and chemotherapy treatment in vivo.
View Article and Find Full Text PDFArticle Synopsis
- Myoglobin (MB) expression in breast cancer is linked to better patient prognosis and its exact role in tumor growth is still not fully understood.
- Researchers used CRISPR/Cas9 to create MB-deficient breast cancer cell lines (MCF7 and SKBR3) and found that loss of MB led to increased cell survival, upregulated cell cycle proteins, and reduced apoptosis, making these cells less responsive to the chemotherapy drug doxorubicin.
- In hypoxic conditions, lacking MB promoted cell migration and invasion, while in human invasive mammary tumors, MB's presence correlated with reduced apoptosis and a more favorable prognosis, suggesting that MB has important tumor-suppressive effects in cancer cells.